NZ616637A - Preparation of high-purity gadobutrol - Google Patents

Preparation of high-purity gadobutrol

Info

Publication number
NZ616637A
NZ616637A NZ616637A NZ61663712A NZ616637A NZ 616637 A NZ616637 A NZ 616637A NZ 616637 A NZ616637 A NZ 616637A NZ 61663712 A NZ61663712 A NZ 61663712A NZ 616637 A NZ616637 A NZ 616637A
Authority
NZ
New Zealand
Prior art keywords
purity
preparation
purity gadobutrol
gadobutrol
gadolinium
Prior art date
Application number
NZ616637A
Other languages
English (en)
Inventor
Johannes Platzek
Wilhelm Trentmann
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46208435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ616637(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of NZ616637A publication Critical patent/NZ616637A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ616637A 2011-04-21 2012-04-17 Preparation of high-purity gadobutrol NZ616637A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011100128 2011-04-21
PCT/EP2012/057013 WO2012143355A1 (en) 2011-04-21 2012-04-17 Preparation of high-purity gadobutrol

Publications (1)

Publication Number Publication Date
NZ616637A true NZ616637A (en) 2016-01-29

Family

ID=46208435

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ616637A NZ616637A (en) 2011-04-21 2012-04-17 Preparation of high-purity gadobutrol

Country Status (34)

Country Link
US (2) US10072027B2 (e)
EP (2) EP2896405B1 (e)
JP (3) JP6096757B2 (e)
KR (3) KR102003570B1 (e)
CN (1) CN103547573B (e)
AR (1) AR086190A1 (e)
AU (2) AU2012244791B2 (e)
BR (1) BR112013027028B1 (e)
CA (1) CA2833659C (e)
CL (1) CL2013003045A1 (e)
CO (1) CO6801752A2 (e)
CU (2) CU24439B1 (e)
DK (1) DK2896405T3 (e)
DO (1) DOP2013000245A (e)
EA (2) EA201600272A1 (e)
EC (1) ECSP13013010A (e)
ES (1) ES2780599T3 (e)
GT (1) GT201300253A (e)
HR (1) HRP20200336T1 (e)
IL (1) IL228885A (e)
LT (1) LT2896405T (e)
MX (1) MX362133B (e)
MY (1) MY163709A (e)
NZ (1) NZ616637A (e)
PE (1) PE20141325A1 (e)
PH (1) PH12013502168B1 (e)
PL (1) PL2896405T3 (e)
PT (1) PT2896405T (e)
RS (1) RS60001B1 (e)
SG (1) SG194511A1 (e)
SI (1) SI2896405T1 (e)
TW (1) TW201249818A (e)
WO (1) WO2012143355A1 (e)
ZA (1) ZA201308706B (e)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143355A1 (en) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Preparation of high-purity gadobutrol
WO2015117911A1 (en) * 2014-02-06 2015-08-13 Agfa Healthcare Process for purifying 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
KR101693400B1 (ko) * 2014-09-17 2017-01-05 에스티팜 주식회사 칼코부트롤의 제조방법
KR101646211B1 (ko) * 2014-11-12 2016-08-05 (주)디아이테크 자기공명영상용 조영제의 제조방법
KR101653064B1 (ko) * 2014-12-26 2016-09-09 에스티팜 주식회사 가도부트롤의 제조방법
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
AU2017333698B2 (en) 2016-09-27 2020-12-24 Bayer Pharma Aktiengesellschaft Method for producing the crystalline form of modification a of calcobutrol
CN106543094A (zh) * 2016-11-04 2017-03-29 嘉实（湖南）医药科技有限公司 高纯度钆布醇的制备方法
WO2018096082A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
GB201703227D0 (en) * 2017-01-20 2017-04-12 Ge Healthcare As Plastic containers
CN109293592A (zh) * 2017-07-24 2019-02-01 天津科伦药物研究有限公司 一种制备钆布醇的方法
KR101971435B1 (ko) * 2017-08-29 2019-04-24 주식회사 엔지켐생명과학 가도부트롤 중간체 및 이를 이용한 가도부트롤의 제조 방법
CN108840832A (zh) * 2018-06-29 2018-11-20 广州康瑞泰药业有限公司 一种钆布醇中间体的制备方法
US12227527B2 (en) 2018-07-10 2025-02-18 Biophore India Pharmaceuticals Pvt. Ltd Process for the preparation of 2,2′,2″-(10-((2R,3S)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid and its complexes
KR102167614B1 (ko) * 2018-08-23 2020-10-19 에스티팜 주식회사 가도부트롤의 제조방법
PE20211471A1 (es) * 2018-11-23 2021-08-05 Bayer Ag Formulacion de medios de contraste y proceso para prepararlos
WO2020122998A1 (en) 2018-12-12 2020-06-18 Medibeacon Inc. Uses of transdermal glomerular filtration rate measurement in continuous renal replacement therapy
GB201919073D0 (en) * 2019-12-20 2020-02-05 Ge Healthcare As Novel manufacturing process
CN113087680A (zh) * 2020-01-08 2021-07-09 威智医药有限公司 Dota晶型及其制备方法
CN113105407A (zh) * 2020-01-13 2021-07-13 北京北陆药业股份有限公司 一种钆布醇新型晶型及其制备方法
KR20210114742A (ko) * 2020-03-11 2021-09-24 주식회사 엔지켐생명과학 칼테리돌의 제조방법
CN114539178B (zh) * 2020-11-26 2024-03-15 江苏恒瑞医药股份有限公司 一种钆布醇的纯化方法
CN114573522A (zh) * 2020-11-30 2022-06-03 江苏恒瑞医药股份有限公司 一种考布曲钙的新晶型及其制备方法
US20220242885A1 (en) * 2021-02-01 2022-08-04 Inventure, LLC Synthesis methods and compositions of low intermediate and low dichelate intermediate contrast agents
CN112939806B (zh) * 2021-03-08 2023-05-16 山东新华制药股份有限公司 一种卡比多巴的精制方法
CN113527223B (zh) * 2021-06-22 2023-05-09 安徽普利药业有限公司 一种钆布醇的精制方法
CN114105897B (zh) * 2021-07-29 2023-04-04 安徽普利药业有限公司 一种钆特醇的制备方法
CN116023345A (zh) * 2023-02-16 2023-04-28 渭南瑞联制药有限责任公司 一种钆布醇中间体杂质的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
NL194579C (nl) 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
DE3625417C2 (de) 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
DE4009119A1 (de) 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US7385041B2 (en) 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
DE4035760A1 (de) 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
DE4237943C2 (de) 1992-11-06 1997-10-23 Schering Ag Verfahren zur Herstellung von Metallkomplexen der N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecan- und N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivate
DE4140779A1 (de) 1991-12-06 1993-06-09 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Verfahren zur herstellung von mono-n-substituierten tetraazamakrocyclen
US5410043A (en) 1991-12-06 1995-04-25 Schering Aktiengesellschaft Process for the production of mono-N-substituted tetraaza macrocycles
DE4218744C2 (de) * 1992-06-04 1997-11-06 Schering Ag Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
IT1275426B (it) 1995-05-16 1997-08-07 Bracco Spa Recupero del gadolinio e dei suoi agenti complessanti da soluzioni acquose contenenti i loro complessi
US5744616A (en) 1996-02-26 1998-04-28 Schering Aktiengesellschaft Process for the production of 1,4,7,10-tetraazacyclododecane and its derivatives
DE19608307C1 (de) 1996-02-26 1997-08-28 Schering Ag Verfahren zur Herstellung von 1,4,7,10-Tetraazacyclododecan und dessen Derivaten
DE19724186C2 (de) * 1997-06-02 2002-07-18 Schering Ag Verfahren zur Mono- und 1,7-Bis-N-ß-Hydroxyalkylierung von Cyclen und die entsprechenden N-ß-Hydroxyalkyl-1,4,7,10-tetraazacyclododecan-Li-Salz-Komplexe
IT1292127B1 (it) 1997-06-11 1999-01-25 Bracco Spa Processo per la dissalazione di sostanze instabili a ph acidi
IT1292128B1 (it) * 1997-06-11 1999-01-25 Bracco Spa Processo per la preparazione di chelanti macrociclici e loro chelati con ioni metallici paramagnetici
EP0985548B1 (fr) 1998-09-08 2002-10-23 Kba-Giori S.A. Machine d'impression de sécurité sur des papiers-valeur
DE10064467C2 (de) 2000-12-15 2002-10-31 Schering Ag Lithium-Komplexe von N-(1-Hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecan, deren Herstellung und Verwendung
DE102009053171B4 (de) 2009-11-04 2011-07-21 Bayer Schering Pharma Aktiengesellschaft, 13353 Verfahren zur Herstellung des Calcium-Komplexes von Dihydroxy-hydroxy-methylpropyl-tetraazacyclododecan-triessigsäure (Calcobutrol)
WO2011054480A1 (de) 2009-11-09 2011-05-12 Bayer Schering Pharma Aktiengesellschaft Gadobutrolherstellung mittels keramischer membran
DE102010013833A1 (de) 2010-03-29 2011-09-29 Bayer Schering Pharma Aktiengesellschaft Herstellung von Gadobutrol mittels Dimethylformamiddimethylacetal
DE102010023105A1 (de) 2010-06-04 2011-12-08 Bayer Schering Pharma Aktiengesellschaft Gadobutrolherstellung im Eintopfverfahren mittels DMF-acetal und N-Methylimidazol
WO2012143355A1 (en) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Preparation of high-purity gadobutrol
KR101653064B1 (ko) 2014-12-26 2016-09-09 에스티팜 주식회사 가도부트롤의 제조방법

Also Published As

Publication number Publication date
ECSP13013010A (es) 2013-12-31
SG194511A1 (en) 2013-12-30
US10435417B2 (en) 2019-10-08
PL2896405T3 (pl) 2020-06-15
SI2896405T1 (sl) 2020-04-30
EA201600272A1 (ru) 2016-12-30
BR112013027028B1 (pt) 2020-08-11
CN103547573B (zh) 2016-08-17
RS60001B1 (sr) 2020-04-30
PT2896405T (pt) 2020-03-31
CO6801752A2 (es) 2013-11-29
CU20160163A7 (es) 2017-02-02
US20140107325A1 (en) 2014-04-17
KR20140035911A (ko) 2014-03-24
EP2699556A1 (en) 2014-02-26
EP2896405B1 (en) 2020-02-19
PH12013502168A1 (en) 2014-01-13
KR102003570B1 (ko) 2019-07-24
GT201300253A (es) 2015-01-16
AU2012244791B2 (en) 2017-04-27
CN103547573A (zh) 2014-01-29
LT2896405T (lt) 2020-03-25
HRP20200336T1 (hr) 2020-06-12
JP2018188477A (ja) 2018-11-29
US20180105537A1 (en) 2018-04-19
AU2012244791A1 (en) 2013-10-31
CA2833659A1 (en) 2012-10-26
AU2017204495A1 (en) 2017-07-20
CU20130142A7 (es) 2014-02-28
KR20190079682A (ko) 2019-07-05
MX2013012290A (es) 2013-11-21
ES2780599T3 (es) 2020-08-26
DOP2013000245A (es) 2013-12-31
JP2017031220A (ja) 2017-02-09
JP2014522387A (ja) 2014-09-04
PE20141325A1 (es) 2014-10-08
IL228885A (en) 2016-11-30
WO2012143355A1 (en) 2012-10-26
HK1193817A1 (zh) 2014-10-03
PH12013502168B1 (en) 2019-11-27
CA2833659C (en) 2019-12-03
MX362133B (es) 2019-01-07
EP2896405A1 (en) 2015-07-22
TW201249818A (en) 2012-12-16
ZA201308706B (en) 2015-08-26
IL228885A0 (en) 2013-12-31
EA026572B1 (ru) 2017-04-28
MY163709A (en) 2017-10-13
US10072027B2 (en) 2018-09-11
EA201301182A1 (ru) 2014-08-29
CL2013003045A1 (es) 2014-05-02
BR112013027028A2 (pt) 2016-12-27
AR086190A1 (es) 2013-11-27
DK2896405T3 (da) 2020-04-06
JP6096757B2 (ja) 2017-03-15
KR20200059319A (ko) 2020-05-28
CU24439B1 (es) 2019-09-04

Similar Documents

Publication Publication Date Title
NZ616637A (en) Preparation of high-purity gadobutrol
MY173877A (en) Branched 3-phenylpropionic acid derivatives and the use thereof
PH12014500164A1 (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
WO2012082718A3 (en) 3-methanesulfonylpropionitrile for treating inflammation and pain
TN2012000544A1 (en) Soluble guanylate cyclase activators
ZA201401568B (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
PL2018379T3 (pl) Sole skopiny oraz ich zastosowanie w sposobach wytwarzania N-demetylo-tiotropium i bromku tiotropium
NZ589350A (en) Novel [F-18]-labelled L-glutamic acid- and L-glutamine derivatives (I), use thereof and method for their production
CA2920410C (en) Thienopiperidine derivative and use thereof
TN2014000001A1 (en) A new therapeutical composition containing apomorphine as active ingredient
NZ602450A (en) Agomelatine hydrochloride hydrate and preparation thereof
MX2014003701A (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
MY160337A (en) Agomelatine hydrobromide hydrate and preparation thereof
PL2291374T3 (pl) Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
WO2011095801A3 (en) Liquid pharmaceutical composition for buccal administration comprising morphine
MX2015006871A (es) Proceso de cristalizacion de derivados de indoles triciclicos.
IN2015DN01463A (e)
WO2011149206A3 (en) Pharmaceutical composition containing crystalline nebivolol hydrochloride and method for preparing the same
WO2012131412A3 (en) Pharmaceutical composition containing no, process for the preparation and use thereof
NZ630795A (en) Crystalline form of vsn16
WO2013054178A3 (en) Extended release pharmaceutical compositions containing carmabazepine
HK1187351A1 (zh) 具有确定粒径的纯的非多晶形晶质胆汁酸的优化合成
AU2013204155B2 (en) Pure erlotinib

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 APR 2019 BY GRIFFITH HACK

Effective date: 20160503

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 APR 2020 BY CPA GLOBAL

Effective date: 20190321

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 APR 2021 BY CPA GLOBAL

Effective date: 20200212

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 APR 2022 BY CPA GLOBAL

Effective date: 20210318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 APR 2023 BY CPA GLOBAL

Effective date: 20220317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 APR 2024 BY CPA GLOBAL

Effective date: 20230316

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 APR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240321

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 APR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250320